Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03721679
Title Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Oncovir, Inc.
Indications

Advanced Solid Tumor

Therapies

Cemiplimab + Poly ICLC

Atezolizumab + Poly ICLC

Pembrolizumab + Poly ICLC

Durvalumab + Poly ICLC

Nivolumab + Poly ICLC

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Chevy Chase RCCA Chevy Chase Maryland 20815 United States Details
Bay Hematology Oncology Easton Maryland 21601 United States Details
Icahn School of Medicine at Mount Sinai New York New York 10029 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field